The cooperation between Chinese and foreign pharmaceutical companies has become more frequent, and the content of cooperation has shown a trend of diversification

【Pharmaceutical Network Industry News】The cooperation between Chinese and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation content is diversified Recently, the signing ceremony of Merck Group's trademark license and the signing of the biological wisdom valley (Chengdu) Technology Co.
, Ltd.
and the launching ceremony of the Merck Empowerment Composite Macromolecule CDMO Project were held
in Wenjiang, Chengdu.
This marks Merck's announcement to establish a partnership with BioIntelligence Valley (Chengdu) Technology Co.
, Ltd.
("BioIntelligence Valley") to jointly promote the construction of the Contract Development and Manufacturing Organization (CDMO) Public Technical Service Platform Project in Chengdu Medical City, and actively contribute to the construction of
Chengdu's biomedical industry.
In recent years, under the drastic policy reforms, China's pharmaceutical and health industry has flourished while also accelerating the pace of opening up, making China an emerging pharmaceutical market with great potential and vitality in the world, which has an irresistible attraction
to foreign enterprises.
It is reported that since the beginning of this year, a large number of domestic and foreign pharmaceutical companies have reached cooperation agreements
.
For example, on September 29, Simcere Pharmaceuticals and Almirall, a veteran European pharmaceutical company, jointly announced that they had reached a licensing agreement for a preclinical autoimmune disease innovation drug developed by Simcere Pharmaceuticals, and Almirall acquired an exclusive interest in the development and commercialization of the drug outside Greater China, and Simcere Pharmaceutical will receive a total milestone payment of up to US$492 million, including a down payment
of US$15 million 。 On August 30, Sinopharm Holdings and Novartis China held a strategic upgrade cooperation seminar and the signing and launching ceremony of the "Within Reach" project at the Sinopharm Holding Building in Shanghai, attended the signing and launching ceremony by Liu Yong, President of Sinopharm Holdings, and Zhang Ying, President of Novartis Innovative Drugs China, and the relevant project team of Sinopharm Holdings' Global Procurement and Supply Chain Service Center, the management and business team of Novartis China's specialty drug retail business attended the signing and launching ceremony
.
On August 16, Qingdao BAHEAL Pharmaceutical Co.
, Ltd.
announced that it signed a renewal agreement
with Takeda (China) Investment Co.
, Ltd.
in Qingdao, China.
Relying on the commercialization capabilities of BAHEAL Pharmaceutical's online and offline markets, the two sides will continue to deepen the commercialization of
Takeda China's brand products including Dakopron ® (Lansoprazole Enteric-Coated Capsules), Pantolok ® (Pantoprazole Sodium Enteric-Coated Tablets), and Putopin ® (Lansoprazole Tablets).
。 On August 5, Cinda Bio announced that it has reached a multi-project strategic cooperation and licensing agreement with Sanofi to cooperate in the development of two high-potential anti-tumor drugs SAR408701 (Tusamitamab Ravtansine; The clinical development and commercialization of anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-α-biased IL-2) in China, including exploring a series of clinical studies in combination with the PD-1 inhibitor Daboshu ® (Xindilizumab injection), with the aim of accelerating the development and market access of innovative therapies to benefit cancer patients in
China.
.
.
.
.
.
.
From the current point of view, the cooperation between domestic and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation content is more abundant, involving products, marketing and other aspects
.
Under the multi-dimensional cooperation, the industry expects that in the future, Chinese and foreign pharmaceutical companies will further accelerate their efforts to "go global" and
"bring in".
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.